Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/9059
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDağlıoğlu, Cenk-
dc.contributor.authorKacı, Fatma Necmiye-
dc.date.accessioned2020-07-25T22:03:22Z
dc.date.available2020-07-25T22:03:22Z
dc.date.issued2019-04
dc.identifier.issn0378-5173
dc.identifier.issn1873-3476
dc.identifier.issn0378-5173-
dc.identifier.issn1873-3476-
dc.identifier.urihttps://doi.org/10.1016/j.ijpharm.2019.02.036
dc.identifier.urihttps://hdl.handle.net/11147/9059
dc.descriptionPubMed: 30825555en_US
dc.description.abstractChemotherapy frequently involves combination treatment protocols to maximize tumor cell killing. Unfortunately these intensive chemotherapeutic regimes, often show disappointing results due to the development of drug resistance and higher nonspecific toxicity on normal tissues. In cancer treatment, it is critically important to minimize toxicity while preserving efficacy. We have previously addressed this issue and proposed a nanoparticle-based combination therapy involving both a molecularly targeted therapy and chemotherapeutic agent for neutralizing antiapoptotic survivin (BIRC5) to potentiate the efficacy of doxorubicin (DOX). Although the particles exhibited strong anticancer effect on the lung carcinoma A549 and the cervical carcinoma HeLa cells, there were lower-level therapeutic outcomes on the colon carcinoma HCT-116, the leukemia Jurkat and the pancreatic carcinoma MIA PaCa-2 cells. Since targeted therapies are one of the key approaches for overcoming drug resistance, tailoring the treatment of cancer cells with distinct characteristics is necessary to improve the therapeutic outcome of cancer therapy and to minimize potential pharmacokinetic interactions of drugs. In the light of this issue, this study examined whether a cascade therapy with low-dose DOX and survivin-targeted tailored nanoparticles is more effective at sensitizing HCT-116, Jurkat and MIA PaCa-2 cancer cells to DOX-chemotherapy than simultaneous combination therapy. The results demonstrated that the sequential therapy with the protocol comprising addition of the nanoparticles after incubation of cells with DOX clearly advanced the therapeutic outcome of related cancer cells, whereas the reverse protocol resulted in a reduction or delay in apoptosis, emphasizing the critical importance of formulating synergistic drug combinations in cancer therapy.en_US
dc.language.isoenen_US
dc.publisherElsevier Ltd.en_US
dc.relation.ispartofInternational Journal of Pharmaceuticsen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNanoparticlesen_US
dc.subjectChemoresistanceen_US
dc.subjectDoxorubicinen_US
dc.subjectSurvivinen_US
dc.subjectColon canceren_US
dc.subjectPancreatic canceren_US
dc.subjectLeukemiaen_US
dc.titleCascade therapy with doxorubicin and survivin-targeted tailored nanoparticles: An effective alternative for sensitization of cancer cells to chemotherapyen_US
dc.typeArticleen_US
dc.departmentIzmir Institute of Technology. Molecular Biology and Geneticsen_US
dc.identifier.volume561en_US
dc.identifier.startpage74en_US
dc.identifier.endpage81en_US
dc.identifier.wosWOS:000462468700008
dc.identifier.scopusSCOPUS:2-s2.0-85062166189
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1016/j.ijpharm.2019.02.036-
dc.relation.doi10.1016/j.ijpharm.2019.02.036en_US
dc.coverage.doi10.1016/j.ijpharm.2019.02.036en_US
item.fulltextWith Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeArticle-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.grantfulltextembargo_20230101-
Appears in Collections:Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File Description SizeFormat 
1-s2.0-S0378517319301590-main.pdf
  Until 2023-01-01
Makale (Article)2.34 MBAdobe PDFView/Open    Request a copy
Show simple item record

CORE Recommender

SCOPUSTM   
Citations

1
checked on Oct 16, 2021

WEB OF SCIENCETM
Citations

6
checked on Oct 16, 2021

Page view(s)

28
checked on Oct 19, 2021

Google ScholarTM

Check

Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.